PTC Therapeutics (NASDAQ:PTCT) PT Raised to $51.00 at Credit Suisse Group

PTC Therapeutics (NASDAQ:PTCT – Get Rating) had its target price increased by Credit Suisse Group from $48.00 to $51.00 in a research report released on Friday morning, The Fly reports. Other research analysts have also recently issued reports about the company. SVB Leerink reissued a market perform rating and issued a $48.00 target price on […]

Related Keywords

Canada ,China ,William Blair ,Davidp Southwell ,Allan Steven Jacobson ,Stuart Walter Peltz ,Lazard Asset Management ,Morgan Stanley ,Securities Exchange Commission ,Altshuler Shaham Ltd ,Kinneret Advisory ,Therapeutics Inc ,China Universal Asset Management Co ,Credit Suisse Group ,Royal Bank ,Get Rating ,Suisse Group ,Marie Utter ,Exchange Commission ,Director David ,Shaham Ltd ,Universal Asset Management ,Asset Management ,South Plainfield ,Ptc Therapeutics ,Nasdaq Ptct ,Ptct ,Medical ,Boost Price Target ,Credit Suisse Group Ag ,